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Dear Editor
Step by Step Improvement of Peripheral
Polyneuropathy Associated with
Churg-Strauss Syndrome by Six
Courses of High-Dose Intravenous
Immunoglobulin Therapy
Churg-Strauss syndrome (CSS) is a systemic vasculi-
tis, developing with peripheral blood eosinophilia un-
der a background of an upper respiratory disease. It
involves multiorgan systems.1 Most of the Japanese
CSS patients develop the peripheral nervous system,
that frequently leaves residual damage as a major
clinical problem, although corticosteroids and cyclo-
phosphamide are efficacious.2
Since a good response to high-dose intravenous im-
munoglobulin ( IVIg) therapy was first reported in
CSS in 1991, several studies have confirmed its effi-
cacy, particularly for peripheral neuropathy.3-5 How-
ever, the optimal number of courses for the satisfac-
tory treatment has not yet been known.
We treated a case of CSS with severe polyneuropa-
thy successfully by six sequential courses of IVIg.
A 61-year-old female, having suffered from bron-
chial asthma for 4 years, felt progressive numbness of
her extremities, developed drop hands and feet, and
became not able to walk at all 3 months before visit-
ing our hospital. On admission to a previous hospital,
she had neither fever, skin eruption, nor chest and
abdominal abnormalities, but a nerve conduction test
of her lower extremities showed reduced amplitudes
of action potentials in distal compound muscle and
sensory nerves. She was diagnosed as having
mononeuritis multiplex. The findings of the manual
muscle strength test (MMT) as defined by the Medi-
cal Research Council scale are listed in Figure 1.
Laboratory data were: peripheral blood white blood
cell count, 32,900μL ; peripheral blood eosinophil
count, 25,470μL; serum C-reactive protein level, 1.0
mgdL; serum IgE level, 2,327 IUmL; rheumatoid
factor level, 631 UmL; and negativity for both the
myeloperoxidase-specific and proteinase-3-specific
anti-neutrophil cytoplasmic antibody, and anti-nuclear
antibody. Analysis of bone marrow aspirates revealed
reactive eosinophilia. These findings and a history of
asthma fulfilled the diagnostic criteria for CSS. Three
courses of pulsed methylprednisolone 1 g for 3 con-
secutive days, followed by oral prednisolone at 1 mg
kgday and IVIg (S-sulfonated gammaglobulin, Ve-
nilonⓇ; Teijin, Tokyo, Japan) at 400 mgkgday for 5
days were administered. Her eosinophil count de-
creased to less than 50μL, IgE level did to 127 IU
mL, and her neurological symptoms stopped pro-
gressing further after having extended from the pe-
ripheries to above the elbows and knees, but there
was no further improvement and she was transferred
to our hospital.
When she was transferred, she had pain, burning
sensation, and numbness of her extremities. She had
paralyses most severely in the bilateral common per-
oneal and radial nerves. MMT findings are listed in
Figure 1. Her score in the modified Rankin Scale
(mRS), which measures the degree of disability or
dependence in daily activities, was 4, which means a
moderately severe disability and inability to walk
without assistance, although a little improvement
from before the first IVIg might be suspected. She
had five additional courses of IVIg approximately
every 6 weeks, whereas oral prednisolone was ta-
pered from 1 month after its start. During the courses
of IVIg, her mRS score improved incrementally
course by course. After the second course of IVIg,
which was the first in our hospital, she could keep
standing just enough by herself. After the third, she
was able to walk using foot orthoses and to go to the
washroom by herself. After the fourth, she was able
to use chopsticks. After the fifth, she was able to walk
for 200 meters at a time. After the sixth, she was able
to go abroad to take care of her grandchild. Her mRS
score became 2, which means slight disability and
ability to look after own personal needs without assis-
tance. Her sensory nerve symptoms became less and
less severe, localized only to the peripheries of her
fingers and toes.
After the sixth course, prednisolone was tapered to
10 mgday, and her disease activity was still con-
trolled well with the eosinophil count being below
50μL.
Peripheral neuropathy develops in 66-95% of pa-
tients with CSS, the most common feature of which
being mononeuritis multiplex. 4 It disrupts patients’
activities of daily living, although CSS seldom has a
fatal outcome.
Recently, IVIg has been shown to be beneficial for
the treatment of CSS-associated neuropathy and car-
diopathy. 4 IVIg is an immunoglobulin preparation
fractionated from pooled plasma from healthy volun-
teers, and is considered relatively safe, even in an in-
fectious condition or during pregnancy.6
IVIg does not directly decrease peripheral blood
eosinophil count. Some case reports show that the
temperature of the extremities measured by ther-
mography increases immediately after IVIg admini-
stration.5 The improvement of blood flow may con-
tribute to that of CSS-associated neuropathy. Further-
more, IVIg down-regulates transforming growth
factor-β and interleukin-4 in mice, which results in
the blockage of fibrosis and may suppress the pro-
gression of fibrinoid degeneration particularly in
small vessels.7
Among the 6 types of immunoglobulin preparation
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Fig.　1　The progress report of her disease. IVIg, intravenous high-dose immunoglobulin; mPSL, methyl-
prednisolone; PSL, prednisolone; Eos, peripheral blood eosinophil count; IgG, immunoglobulin G; mRS, 
modifi ed Rankin Scale; Delt, deltoid; Bi, biceps brachii; Tri, triceps brachii; WE, wrist extensors; WF, wrist 
fl exors; FE, fi nger extensors; FF, fi nger fl exors; Iliops, iliopsoas; Quad, quadriceps; TA, tibialis anterior; 
GC, gastrocnemius; EHL, extensor hallucis longus.
IVIg 17.5 g
× 5 days
mPSL 1 g
× 3 days
PSL 60
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 Delt 3/4 5/5 5/5 5/5 5/5 5/5
 Bi 5/5 5/5 5/5 5/5 5/5 5/5
 Tri 5/4 5/4 5/5 5/5 5/5 5/5
 WE 1/1 1/2 1/3 3/4 4/4 4/4
 WF 4/4 4/4 4/4 4/4 4/4 4/4
 FE 0/0 2/2 2/2 2/2 2/2 3/3
 FF 4/4 4/4 4/4 4/4 4/4 4/4
 Iliops 4/4 4/4 4/4 4/4 4/4 4/4
 Quad 4/4 3/4 4/4 4/4 5/5 5/5
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available in Japan, S-sulfonated gammaglobulin con-
tains IgG dimers the most and is the only preparation
for on-label use for CSS. Dimeric IgG is reported to
be efficacious for treating idiopathic thrombocy-
topenic purpura in comparison with monomeric IgG
through the blockade of the Fcγ receptor.8 The block-
ade would control autoantibody-mediated pathogene-
sis. As autoantibodies are also involved in CSS,
dimeric IgG-rich preparations could be related to the
recovery from CSS-associated neuropathy.
In Kawasaki disease, some reports state that the
extent of increase in IgG level from immediately be-
fore to after IVIg therapy might be an indicator for
evaluating its effect.9 In our patient, the IgG level in-
creased linearly after each course of IVIg (Fig. 1).
Measurement of this change would be better con-
ducted and compared in relation to the improvement
of neuropathy.
In this case, a course by course incremental effect
of IVIg on CSS-associated polyneuropathy was clearly
observed even in its late phase. Although the underly-
ing mechanism have yet to be determined, repeated
administrations of IVIg, even if expensive at present,
would be quite effective for CSS-associated neuropa-
thy.
Hiromitsu Asashima1, Shigeko Inokuma1 and
Hiroki Yamada2
IVIg on CSS-Associated Polyneuropathy
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